Importantly, this form of diabetes occurs more frequently with anti-PD-1 and anti-PD-L1 therapies than with other forms of immune checkpoint inhibitors, underscoring the specific risks associated with PD-1 /PD-L1 inhibition. This evidence concerns the gene PDCD1 and diabetes mellitus.